Ember Therapeutics (OTC: EMBT) is a biopharmaceutical company whose primary focus is on utilizing Bone Morphogenetic Protein-7 (BMP-7) and related family of BMPs, mutants, variants, novel formulations, and delivery technologies to develop regenerative medicines for disease modification of osteoarthritis, reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases such as chronic kidney disease and Alport Syndrome. The company believes BMP-7 represents a new class of therapeutics and may be transformative in the treatment of these diseases. For more information, visit the company’s website at www.embertx.com